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HIV Protease Inhibitors
The human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of acquired
immunodeficiency syndrome (AIDS). The discovery of clinically effective HIV protease
inhibitors has significantly improved the lifestyles of many individuals afflicted with the virus.
Nevertheless, current protease inhibitors suffer to some extent from issues not limited to first-
pass metabolism, toxicities and food restrictions which often contribute to patient non-
compliance. Recently the emergence of multi-drug resistant viral variants has been confirmed,
further compromising the effectiveness of current PI therapy. In an effort to produce
compounds possessing improved pharmacokinetic and potency profiles, a combinatorial library
of compounds targeting HIV protease inhibition was synthesised (Combinatorial
diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library, T. A.
Rano et. al., Bioorg. Med. Chem. Lett., 10, (2000), 1527-1530). A library of 60 compounds
was synthesised in mixtures of 20 on Rapp TentaGel S CO2H resin.
These compounds were tested in mixtures of 20 using in vivo dosing of multiple component
mixtures, for their ability to prevent cleavage of a substrate by the protease enzyme (IC50) and
to inhibit the spread of viral infection in MT4 human T-lymphoid cells infected with the IIIb
isolate (CIC95). Of those mixtures tested, the most active gave an enzyme inhibition IC50 of 1.1
nM, and a value for the inhibition of viral spread (IIIb) CIC95 of 200 nM. The success of this
library is in providing a step forward towards the identification of a second generation HIV
protease inhibitor possessing improved metabolic and potency profiles.
--------------------------------------------------------------------------------------------------------------
Cell-permeable molecules
Small molecules that induce or stabilise the association of macromolecules hold promise as
biological effectors. Such 'chemical inducers of dimerisation' (CIDs) are well known in Nature;
anti-cancer agents adriamycin and etoposide act by stabilising a catalytic intermediate having
topoisomerase II bound to its nicked DNA substrate. The immunosuppressive agent FK506
induces the dimerisation of FK506-binding protein (FKBP) and calcineurin (Cn), thereby
abrogating the latter's protein phosphatase activity. The potential of designed synthetic CIDs
to bring together signalling proteins in a spatially and temporally controlled manner gives the
ability to engineer a variety of inducible signal transduction processes into cells. These
synthetic 'dimerisers' all involve bifunctional molecules having two ligand moieties linker
together, each of which binds a known receptor. There is also the possibility to induce the
association of one known macromolecule with an unknown one, thereby creating biological
relationships that nature may not have explored. Dimerising two known macromolecules can
present a challenge when a ligand is known for one partner but not the other. Both of these
lines of research could be pursued by the construction of bifunctional small-molecule libraries
having an invariant ligand attached to a diversified ligand whose structure varies among the
members of the library. A combinatorial chemistry approach was used to construct the first
such diversified library of synthetic candidate heterodimerisers (A synthetic library of cell-
permeable molecules, G. L. Verdine et. al., J. Am. Chem. Soc., 123, (2001), 398-408). A
library of 320 individual compounds was synthesised on Trityl-chloride solid phase resin. For
synthetic heterodimerisers to be useful in biological assays with intracellular targets, they must
be cell-permeable. To assess the cell permeability of these library compounds, cells that
express two FKBP fusion proteins - one containing the ZFHD1 DNA-binding domain and the
other containing the p65 acidic transcriptional activator domain - were used. The small-
molecule heterodimer AP1889 brings these two protein components together, thereby
activating transcription of the downstream encoding secreted alkaline phosphatase (SEAP). A
randomly chosen sub-set of the library comprising 25 heterodimers was screened separately at
500 nM concentration. Each of the compounds tested strongly inhibited SEAP expression,
indicating cell-permeability and suitability for use in biological screens. Future research is
directed at determining whether any of these 320 library members will function as
heterodimers, allowing the possibility of engineering a variety of inducible signal transduction
processes into cells. Studies are ongoing in a variety of biological assay systems to address
these aims.
